Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

(Photo Credit: Dr P. Marazzi/Science Source) It's possible to have lupus skin rashes all over your body. Or you may get red, scaly patches or a red, ring-shaped rash, especially where your skin ...

Rashes and other skin changes may be a sign of COVID-19, in addition to classic symptoms like a cough, fatigue, fever, and sore throat. Some people develop a COVID rash, which can appear on body ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Different types of skin rashes include those caused by allergic reactions, infections, insect bites, or health conditions. Examples include eczema, chickenpox, psoriasis, and shingles. It can be ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

Ivonescimab achieves hazard ratio of 0.51, beating pembrolizumab in progression-free survival. Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034. JMP ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...